IPO profile
Himalaya Nutravedics India Limited
HNIL · BSE
- Price band
- ₹100 - ₹106
- Subscription
- Not available
Application & Issue Details
- Minimum Quantity
- 1200 shares
- Minimum Application
- ₹1,27,200
- Issue Size
- Rs. 27 Cr
- Face Value
- Not available
Company Overview
Himalaya Nutravedics manufactures and supplies a range of Ayurvedic and nutraceutical products across multiple dosage forms, including softgel capsules, hardgel capsules, tablets, liquid orals, medicated oils, and protein powders. The company operates through a single integrated manufacturing facility located in Hyderabad, Telangana. Its product portfolio covers therapeutic categories such as pain management, infertility, women’s wellness, gut health, neurological support, and general wellness. The business generates revenue primarily from the sale of Ayurvedic formulations, alongside nutraceutical offerings. The company operates mainly through a business-to-business model, supplying products to stockists, distributors, and third-party contract manufacturing clients across various states in India. It also undertakes custom contract manufacturing for corporate clients under their own brand names utilizing its manufacturing infrastructure. Furthermore, the company is expanding its market presence into direct-to-consumer sales channels through digital platforms, e-commerce marketplaces, and quick commerce delivery services.
Important Dates
- Open Date
- 22 Sept 2026
- Close Date
- 24 Sept 2026
- Allotment Date
- Not available
- Listing Date
- 29 Sept 2026
Issue Timeline
- Issue open date
- Issue close date
- UPI mandate deadline
- Allotment finalization
- Refund initiation
- Share credit
- Listing date
- Mandate end date
- Lock-in end date for anchor investors (50%)
- Lock-in end date for anchor investors (remaining)
Subscription
Subscription data not available yet.
Actual Listing Performance
- Listing Date
- 29 Sept 2026
- Actual Listing Price
- ₹118
- Gain/Loss Per Share
- +₹12
- Gain/Loss Per Lot
- +₹14,400
- Listing Gain/Loss %
- +11.32%
- Measured Against
- ₹106
- Lot Size
- 1200 shares
Historical result from the reported listing price, compared with the upper price band (final issue price not reported). Excludes brokerage, taxes and charges.
Company Strengths & Risks
Reported strengths
- Integrated manufacturing facility capable of producing multiple dosage forms.
- Diverse Ayurvedic and nutraceutical product portfolio across key therapeutic areas.
- Established B2B distribution network with presence across 17 Indian states.
- Track record of strong revenue and net profit growth over recent fiscal years.
- In-house quality assurance and control capabilities across production processes.
Key risks
- High revenue reliance on Ayurvedic products, accounting for over 90% of sales.
- Significant revenue concentration from top 10 customers representing over 80% of revenue.
- Operations from a single leased manufacturing facility located in Hyderabad, Telangana.
- Pending trademark opposition proceedings for corporate logos and mark applications.
- History of negative cash flows from operating activities due to working capital needs.
Company strengths and risks are informational summaries. Review the offer document for complete disclosures.
Documents & Coverage
IPO data last updated 25 Oct 2026, 12:08 pm IST · listing price: NSE/BSE
This page is for informational and educational purposes only. It is not investment advice and not a recommendation to buy, sell, or apply for this IPO. GMP and subscription figures are unofficial/may change. Please make your own independent decision.